Pyridoxal Isonicotinoyl Hydrazone (PIH) and Its Analogues: A New Group of Effective Chelators
Iron, which is involved in many metabolic processes including transport and storage of oxygen and oxidation-reduction reactions is an essential element for all living cells with the one possible exception lactic acid bacilli. However, organisms are not equipped with active excretory systems for iron and, therefore, if excessive amounts of iron get to the organism they accumulate without being excreted. This results in an iron overload which is a common finding in patients with refractory anemias such as thalassemia major, some other hemoglobinopathies and certain other anemias1 – 4. The overload is a consequence of increased iron absorption, but primarily of long-term transfusion therapy. Excess iron accumulates in liver, heart and endocrine glands causing serious dysfunction and death. Excess iron is removed from such patients by administration of chelating agents, primarily desferrioxamine. However, since desferrioxamine is inadequate and expensive, new iron chelating agents are needed5.
KeywordsIron Overload Aromatic Aldehyde Refractory Anemia Excess Iron Thalassemia Major
Unable to display preview. Download preview PDF.
- 1.A. W. Nienhuis, Moderator, Thalassemia major: molecular and clinical aspects, Ann. Intern. Med. 91: 883 (1979)Google Scholar
- 2.A. Jacobs, The pathology of iron overload, in: “Iron in Biochemistry and Medicine II”, A. Jacobs and M. Worwood, eds., Academic Press, New York, pp. 427–459 (1980).Google Scholar
- 3.T. H. Bothwell and R. W. Charlton, A general approach to the problems of ifon deficiency and iron overload in the population at large, Seminars Hematol. 19: 54 (1982).Google Scholar
- 4.A. V. Hoffbrand, Transfusion siderosis and chelation therapy, in: “Iron in Biochemistry and Medicine II”, A. Jacobs and M. Worwood, eds., Academic Press, New York, pp. 499–527 (1980).Google Scholar
- 7.P. Ponka, J. Borova, J. Neuwirt, 0. Fuchs, and E. Necas, A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents, Biochim. Biophys. Acta 586: 278 (1979).Google Scholar
- 10.L. Baker, M. L. Vitolo, and J. Webb, Hepatocytes in culture as an in vitro screen for iron chelators: Evaluation of analogues of PIH, in: “Structure and Function of Iron Storage Proteins”, I. Urushizaki, P. Aísen, I. Listowsky, and J. W. Drysdale, eds., Elsevier, pp. 457–460 (1983).Google Scholar
- 13.P. Ponka, M. Gauthier, F. L. Chubb, and Edward, T. J., Synthesis and characterization of iron-chelating acylhydrazones derived from pyridoxal isonicotinoyl hydrazone (PIH), J. Chem. Eng. Data, submitted for publication.Google Scholar
- 14.F. Wild, in: “Characterization of Organic Compounds, 2nd ed.”, Cambridge University Press, p. 110 (1958).Google Scholar